New hope for hard-to-treat leukemia: drug combo enters phase 2 trial
Disease control
Recruiting now
This study tests a new combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people with a type of acute myeloid leukemia (AML) that has returned or not responded to previous treatment. The goal is to see if this combination can help more patients achieve remi…
Phase: PHASE2 • Sponsor: Joshua Zeidner • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC